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graduating in May 2019. Following graduation, Brian will commence his PGY1 residency at IU Health Bloomington
Hospital, with interests in cardiology and emergency medicine.
Monica L. Miller is a clinical associate professor at Purdue University, and served as a faculty mentor for this project.
Sotiris Antoniou is a consultant pharmacist in cardiovascular medicine, and the active site lead pharmacist at St. Bartholomew’s
Hospital in London, UK, where this project originated.
Jagjot Chahal and Sadeer Fhadil are highly specialist cardiac pharmacists at St. Bartholomew’s Hospital and contributed to
the project’s design and implementation. In this article, the authors describe their service-learning project aimed at increasing
public understanding of atrial fibrillation and identifying potentially high-risk patients in a nonclinical setting.
Atrial fibrillation (AF) is a common cardiac/heart disease
that increases a person’s risk of death, making early
identification significant in overall disease management.
Throughout my time in pharmacy school, I [Brian] have
developed an interest in cardiology and research. During
my last year of pharmacy school, I spent eight weeks at
St. Bartholomew’s Hospital in London, one of the largest
cardiac centers in Europe, on an experiential training
experience. While there, I had the opportunity to study
specifics about many cardiac illnesses, with a focus on
atrial fibrillation, and provide education to patients living
with this disease. In addition to working with patients
and expanding my knowledge, I participated in an exciting research project that allowed me to connect with

the general population and share my knowledge about
arrhythmias, which is something I would like to continue
to do after graduation.
Our research project aimed to identify the role pharmacists could play in early detection of arrhythmias,
particularly atrial fibrillation, and increase the population’s awareness and understanding of this illness. For our
project, a pharmacist or student pharmacist was partnered
with nursing staff to provide opportunities for heart rate
and rhythm monitoring as well as individualized education to help ensure interested patients were more aware
of the risks, signs, and symptoms of atrial fibrillation
going forward. When patients met with the team, they had
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their heart rhythms assessed using the AliveCor Kardia
single-lead electrocardiogram (ECG) system. This new
technology allows patients to place their fingers on a small
strip that is able to accurately assess a person’s heart rate
and rhythm to identify any irregularities/arrhythmias.
Participants were also provided education about atrial
fibrillation in hopes of preventing significant m
 orbidity
and mortality, raising awareness about this particular
disease and connecting patients with care. Part of this education included us showing the patients how to manually
take an accurate pulse reading, and how to differentiate
between a normal and irregular rate and rhythm. By teaching the patients these skills, they now know what to look
for, how to monitor their own pulse, and when to seek
help in the event they, or someone they know, experience
symptoms of atrial fibrillation.
INTRODUCTION
Pharmacists are health professionals who have widespread access to the general population in community
and ambulatory care settings as well as within hospitals.
Recent data from Forbes highlights that pharmacists
remain one of the most trusted and ethical professions
behind nurses and physicians (McCarthy 2019). Given
their easy accessibility, connection to the community,
and understanding of medications, they are a trusted
resource for many people. Pharmacists are able to
provide education on a variety of disease states including cardiac conditions such as atrial fibrillation (AF),
an irregular heart rhythm, as well as any related medications. They are also a medication resource for other
health care professionals such as physicians, physician
assistants, and nurses and are often consulted to assist
in medication selection and monitoring. Pharmacists
are well placed to aid in identifying patients at high risk
for certain diseases, given the right technology, and are
able to provide appropriate referrals for needed medical management. They are especially well placed to be
able to identify patients with asymptomatic diseases who
wouldn’t have reason to suspect such a serious health
issue. Uncovering these conditions early could help
patients by preventing a potentially debilitating or fatal
consequence of their disease.
One disease state that pharmacists can aid in detecting
and managing is atrial fibrillation (AF). AF is a cardiac
disease that occurs when the atria of the heart receive
disordered electrical impulses, which in turn cause the
heart to beat irregularly and pump blood less efficiently
(January 2014; National Institute for Health and Care
Excellence [NICE] 2014). This irregular heartbeat
can cause various symptoms including palpitations,
80

shortness of breath, tiredness, chest pain, dizziness, and
blood clots. The blood clots are often a cause of strokes
(Miller 2005; Lin 1996). Patients living with AF are at a
fivefold increase of having a stroke and comprise about
one third of all ischemic stroke patients (Freedman 2016;
Wolf 1991; Kannel 2008). Aside from the increased
risk of stroke, AF also triples a patient’s risk of heart
failure (Stewart 2002) and presents patients with nearly a
twofold-increased risk of mortality (Benjamin 1998). All
of these illnesses can decrease a person’s longevity and
increase their overall health care costs.
Globally, atrial fibrillation is the most commonly identified heart rhythm disturbance and its prevalence is
predicted to rise in the coming years (Morillo 2017;
Chugh 2014). A systematic review published in 2010
analyzed 184 population-based studies published from
1980–2010 from the 2010 Global Burden of Diseases,
Injuries, and Risk Factors Study. This analysis showed
that in 2010, worldwide prevalence of AF was estimated
to be at 33.5 million individuals, with males (20.9 million) being more affected than females (12.6 million)
(Chugh 2014). This study also revealed the median
percentage change of AF has increased by roughly 5%
globally from 1990 to 2010, with the prevalence increasing from 452 to 474 patients per 100,000 (Chugh 2014).
While the global prevalence of AF appears to be growing, it is currently more common in higher-income and
more developed countries (Morillo 2017). The United
States has the greatest prevalence of AF with approximately 2% of the population under the age of 65 years
old and 9% of the population above the age of 65
expected to be affected (Centers for Disease Control and
Prevention 2003). By 2030, as the population continues
to age, the Centers for Disease Control and Prevention
expect this number to increase to 19.6% of people over
the age of 65 years old (Centers for Disease Control and
Prevention 2003; Morillo 2017; January 2014). While the
prevalence of AF in the United Kingdom is lower than in
the United States, the U.K. does have the highest percentage of death contributed to AF, with just over 0.9%
of deaths being associated with AF and atrial flutter in
2010 (Morillo 2017).
To combat the growing prevalence and associated
morbidity and mortality of AF, organizations such as the
Atrial Fibrillation Association, the Arrhythmia Alliance,
and the International Pharmacists for Anticoagulation
Care Taskforce have made coordinated efforts to identify
patients at high risk for AF and refer them for appropriate treatment. One method being trialed is the use of
mobile, single-lead electrocardiogram (ECG) tools to
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Figure 1. AliveCor Kardia system in use.

screen patients before they encounter an adverse event
from AF. The AliveCor Kardia (Kardia) system (Figure
1) is one such tool with high rates of accuracy that is also
easy to use, less invasive than traditional ECG monitors,
and readily available (Koshy 2018). The Kardia system
reads heart rate and rhythm from a person’s fingertips
and sends real-time data directly to a smartphone running the partnered Kardia software application. After
30 seconds, the Kardia program will interpret the reading
and provide an evaluation of “Normal,” “Possible Atrial
Fibrillation” (indicating a rhythm consistent with AF)
or “Unclassified,” (indicating the potential presence of a
non-AF arrhythmia).
In this study, we examined the role pharmacy team
members could have using such a system to screen for
high-risk patients outside of the hospital. Since many
pharmacists interact with patients in a community or
ambulatory care, having the ability to accurately screen
for AF allows for increased patient access and potentially quicker connection to needed medical care.
METHODOLOGY
This multicenter AF screening study was conducted
in various locations in Greater London, England. Data
was collected in 2017–2018 during heart awareness
and “Know Your Pulse” awareness campaigns at Saint
Bartholomew’s Hospital, Moorfield Hospital, Redbridge
Hospital, and SCCP Hospital (Figure 2). These campaigns consisted of weeklong pulse screenings at stations
positioned in the common areas of these facilities and
opened to all interested individuals over the age of 18
regardless of their medical history. Pharmacists, cardiology nurses, and pharmacy learners conducted these

Figure 2. Monica and Brian taking part in an AF screening.

screenings with support from the Arrhythmia Alliance,
who provided educational material to be distributed to
patients.
Upon screening acceptance and before screening, patients
completed an informed consent form. Basic demographic
information recorded included age and gender as well
as identification of common AF symptoms including
palpitations, shortness of breath, tiredness, chest pain,
dizziness, and irregular pulse. Medical history such as
high blood pressure, heart muscle disease, diabetes,
peripheral artery disease, stroke, transient ischemic
attack, clot in the body (excluding lungs), heart attack,
and medication history with a focus on antiplatelet and
anticoagulation drugs were documented. Patients were
educated on the basic disease state information including presenting symptoms and how to detect their own
pulse and heart rate properly. During the screening, each
patient’s heart rate and pulse were recorded after manual
assessment.
Patients were then assessed using the Kardia system to
screen for AF and other potential arrhythmias. Patients
receiving a “Normal” heart rhythm and an acceptable
heart rate were classified as not currently being suspected of AF or further arrhythmia and were permitted to
research with reflection 81
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leave without any need for acute follow up. Patients that
displayed an “Unclassified” or “Possible Atrial Fibrillation” heart rhythm were reassessed using the Kardia. If
the irregularity was duplicated and the patient remained
as “Unclassified” or “Possible Atrial Fibrillation,”
the ECGs were reviewed in detail and the patient was
referred for a full 12-lead ECG workup via their primary
care physician or current hospital site if available. Upon
referral, if AF was confirmed, anticoagulation therapy
was recommended by the pharmacy team in accordance
with national guidelines.
The primary endpoint for this study was to assess the role
pharmacy team members could have in providing early
detection of AF and subsequent referral to care using the
Kardia single-lead ECG system in a nonhospital setting.
This was assessed by the number of patients identified
as having potentially abnormal ECGs that were screened
and referred to further care using the Kardia system.
St. Bartholomew’s Health Clinical Effectiveness Unit
granted ethical approval for this study.
RESULTS
This study enrolled 1,298 patients, of which 154 were
excluded due to incomplete data collection, leaving
1,144 patients available for analysis. Despite exclusions,
all 1,298 patients did receive one-on-one arrhythmia
counseling and education from a pharmacist, pharmacy
learner, or cardiac nurse. Figure 3 highlights the number of patients screened at each location. The 1,144
patients with complete data had a mean age of 55 years,
a median age of 57 years, and a range of 18–101 years
old. Approximately one third of this population was considered elderly, with 371 (32.4%) being ≥65 years old.
When assessed by gender, more males were screened
(639) compared to females (505), with men making
up 55.9% of the patient cohort. The most commonly
reported risk factors were hypertension, peripheral artery

Figure 4. AliveCor Kardia screening results.

disease, and diabetes, which were reported in 29.5%,
15.0%, and 13.1% of the population, respectively.
Figure 4 highlights the results from the Kardia screenings. Of the 1,144 analyzed profiles, 37 patients (3.2%)
were identified as potentially or knowingly being in AF.
Of these, 25 (67.6%) were ≥65 years old at the time of
screening, and 23 (62.2%) were previously unaware of
their likely AF status. An additional 62 patients (5.4%)
were screened and found to potentially have an irregular, but non-AF, heart rhythm. In total, 99 patients were
identified as having a potential arrhythmia and referred
to further care as a direct result of pharmacist and pharmacy learner led ECG screenings. The remaining 1,045
patients (91.4%) were shown to have a “Normal” heart
rhythm interpretation upon screening.
DISCUSSION
The 99 patients identified with an abnormal heart rate
represent approximately 3.2% of the total population
screened. This result is higher than the 1.6% of the
population of England as predicted by NICE in 2013
(National Institute for Health and Care Excellence 2013).
The variance could be potentially explained by the high
percentage of patients taken from an urban e nvironment,
where rates of AF tend to be higher. In addition, a screening site located in one of the largest cardiac centers in
Europe could have led to a population more skewed
towards having cardiovascular conditions. Furthermore,
patients with preexisting heart conditions at this facility
accompanied by family members with similar genetic
risks may be more likely to be visiting the hospital where
a majority of the screenings were held.
COMMUNITY IMPACT

Figure 3. Atrial fibrillation screenings by location.
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This service-learning project was originally designed to
help assess the role pharmacy team members could have
in early detection of AF, but by the end of this project
much more was accomplished. By this study’s conclusion
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nearly 1,300 community members received personal education about a disease state that is predicted to become
more common and has the potential to cause significant
morbidity and mortality issues for affected patients. In
addition to the 1,288 citizens who received this individual
education, many more family members and caretakers,
who were present with their loved ones at the time of
counseling but deferred to take part in the study, learned
about AF and will be able to share what they learned
with others they care about. This is especially important
considering that the United Kingdom has the highest
rate of death attributed to AF globally, with nearly 1 in
100 deaths being attributed to the disease. Directly, 37
patients were identified as being potentially in AF, 18 of
whom were previously unaware and not receiving appropriate medical care guided at minimizing the potential
risks of AF such as stroke and other cardiovascular disorders. More importantly than identifying these patients
was the immediate connection to further care that was
offered to ensure proper risk reduction strategies could be
implemented in this patient group.
While the patients identified as potentially being in a
state of arrhythmia likely received the most benefit from
this service-learning project, the remaining patients in
the “Normal” Kardia screening group also benefitted
greatly. Aside from the verbal education, this group had
the opportunity to see their ECG being taken in real
time, which was a very exciting and interesting experience for many of these patients. This unique screening
tool is what initially piqued many patients’ interest, and
that initial interest is what opened the door to many of
the great discussions and questions that took place. The
Kardia’s ability to display the patient’s heart rhythm
for them to see was a new and very unique experience
for many of the participants. Being able to follow the
rhythm and beat of their heart on the spot was a great
way for patients to make the connection between the
education we provided and themselves, making our
efforts much more relevant for many of them. The enjoyment expressed by the patients also lends to the idea of
them being more willing to participate in similar public
health initiatives in the future.
While this service-learning project was largely successful and benefitted numerous people, there were some
barriers that could be better anticipated for similar
service-learning events in the future. One improvement to be made for future screening efforts would be
to better track patient outcomes after they were identified as potentially arrhythmic and referred on to further
care. While the AliveCor Kardia screening system is
considered to be quite accurate, being able to confirm

and document a patient’s official diagnosis following
their 12-lead screening would be valuable information.
As participant names were not recorded and tied to their
screening results during this project for anonymity, this
information was hard to collect retrospectively. Future
versions of this service-learning project will likely see
a higher level of follow-up for patients with potential
arrhythmias, in order to ensure they receive proper
treatment and to better quantify the results of such a
screening program. Another target for future screening
events would be to have the ability to offer immediate follow-up with a full, 12-lead ECG at all screening
locations. While the majority of participants in this study
were assessed at St. Bartholomew’s where this service
was readily available, being able to offer this convenience to all patients deemed to be at higher risk could
help increase the rate of follow-up care in any upcoming
screening events.
Another challenge was presented by the fact that
multiple parts of the screening and accompanying
questionnaire were dependent on patient-reported
responses. While interviewing patients, it was easy to
see the varying amount of knowledge some participants
held regarding their own health, which could impact the
quality of the data received from the patient interviews.
This was especially apparent for questions regarding less
common risk factors or comorbidities such as peripheral
artery disease or venous thromboembolisms. This variable would be difficult to eliminate in such a nonclinical
setting, but there is potential for screening services similar to this one to be carried out in lower acuity medical
settings such as ambulatory care or general practitioners’
offices, where access to more reliable information could
be readily available.
STUDENT IMPACT
On a more personal note, I [Brian] joined this service-
learning project while on my experiential training
experience as a student who was beginning his journey
into clinical practice. Being able to start my rotations
with such a unique practice site and project helped
prepare me for the rest of my clinical requirements. As
a new rotation student, the opportunity to educate and
interact with such a diverse patient population was a
terrific experience for me to have right out of the gate.
Being able to personally educate 63 patients in a matter of a few days allowed me to gain a confidence in
interacting with patients that I was able to carry with
me through the rest of my experiential training. Aside
from gaining in my own clinical competency regarding patient counseling, I was also able to contribute as
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a core member of an interprofessional team as I collaborated closely with preregistration pharmacists and
specialized cardiac nurses throughout the project. Being
able to work with other health care team members is a
vital skill to have in any capacity as a pharmacist, and
this experience will help me acclimate to other health
care teams as I continue to advance in my career and
ensure patients receive the best outcomes possible as I
practice in the future.
CONCLUSION
In summary, this service-learning project was mutually
beneficial to both the community and myself [Brian] to
a further extent than I would have ever imagined when I
was first introduced to the project. I was able to experience an entirely new health care system firsthand, meet
and educate patients that were genuinely interested
in our project, and learn from fellow health care team
members at the top of their fields, all while providing
valuable education to members of the community. The
authors hope that this article helps to raise awareness
regarding atrial fibrillation and its associated morbidity and mortality, while also providing ideas for others
to help educate and provide for patients in their own
communities.
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